TKI+Cardunilimab

Phase 1Monoclonal antibody

PPeking Union Medical College Hospital

TKI+Cardunilimab is one of 5 small molecule programs targeting Hepatocellular Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CancerRecruiting

Hepatocellular CancerPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Hepatocellular Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

2 2

Zanzalintinib

Merck & Co.

Phase 2

1 3

Yervoy

Bristol-Myers Squibb

Phase 1

1 4

SHR-1826

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 5

TKI+Cardunilimab

PPeking Union Medical College Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hepatocellular Cancer

NCT06363006

Clinical

Trials by Indication[1]

Hepatocellular Cancer1 trial

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT06363006·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TKI+Cardunilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TKI+Cardunilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TKI+Cardunilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: PPeking Union Medical College Hospital

TKI+Cardunilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hepatocellular Cancer1 trial

References

Drug Info

Quick Facts

Related News